Bangalore, INDIA: Subex Ltd, a leading global provider of Business Support Systems (BSS) for Communications Service Providers, announced today that it has recorded strong growth and profitability in its Continuing Product Business (Business Optimization or RMS). Revenue for this segment has grown 26% Y-o-Y. Consequent to the sale of its Activation products, the company will put more emphasize in Business Optimization or RMS. This segment, which is the area in which the company has been operating traditionally, is the fastest growing segment in telecom BSS space.

The Product Revenue for the company stood at Rs. 1177.65 mln (USD 25.18 mln) contributing to 91.37 % of the consolidated revenue. The company posted a Product EBITDA of Rs. 381.66 mln (USD 8.16 mln) i.e. 32.41% while the EBITDA for Continuing Product Business (Business Optimization or RMS) was Rs. 451.81 (USD 9.66 mln) i.e. 41.7%.

The company was declared market leaders in Business Optimization for the fourth consecutive year by renowned analyst firm Analysys Mason. Business Optimisation includes fraud, revenue assurance, analytics, cost management and credit risk management, which together constitutes the core business of the company.

Commenting on the business, Subash Menon, Founder Chairman, Managing Director and CEO, said, “The results for this quarter are extremely promising, as expected. We sold off our activation business this quarter and have renewed our focus on our core business. There is increasing uptake for our industry-changing Revenue Operations Center (ROCTM) and Managed Services offering and the non-linearity in the business continues to help us.”

He further added, “With the sale of the Activation products which were a drag on our core business, the real growth and profitability in the latter will be obvious in the coming quarters. The strong EBITDA of around 40% in this business will lead to significant cash generation in the future and increase our ability to invest for growth.”

lso t�dcn
@�P�zational silos, enabling various entities across the enterprise to collaborate closely on CIA initiatives.

Using the MetricStream solution, the pharmaceutical company will be able to streamline and accelerate policy creation, management and review; efficiently map the policies to Federal healthcare and FDA requirements; and organize them in a centralized Web-based repository with easy access and search capabilities.

The solution will also enable the company to proactively monitor and detect sales force risks through Key Risk Indicators (KRIs), with automatic notifications indicating whenever thresholds are breached.

In addition, the solution will help streamline the complete audit lifecycle to assess the effectiveness of the company’s compliance measures and controls. Issues that arise out of audit findings will be automatically routed through a systematic process of investigation, corrective action and resolution.

Powerful dashboards with drill down functionalities will help in tracking the status and results of various CIA compliance processes in real-time. In turn, flexible reporting capabilities will simplify the process of internal and external reporting by automatically generating reports such as the OIG-mandated Implementation and Annual reports.

With the MetricStream solution, the company will be able to build a sustainable Ethics and compliance management program. In the long run, the company can seamlessly extend the solution to manage its Enterprise Risk Management, Audits, Financial Compliance, FDA requirements, GXPs and drug safety standards, Quality Management, IT, Privacy and Security needs all on one Integrated GRC platform from MetricStream.